Vascular endothelial growth factor (
VEGF) seems to play a central role in angiogenesis-lymphangiogenesis in
hematological malignancies. There are limited data related to childhood
hematologic malignancies. The aim of the study was to evaluate soluble
VEGF (sVEGF) levels in children with acute
leukemia and
malignant lymphoma (ML) at diagnosis and in remission. The levels of serum sVEGF were measured by
enzyme-linked
immunosorbent assay (ELISA) in 20 children with acute
leukemia, 33 children with different histopathological subtypes of ML, and 20 healthy controls. The levels of sVEGF at diagnosis (range 2 -1040 pg/mL; median 52 pg/mL) was significantly lower than in remission (range 136 -1960 pg/mL; median 630 pg/mL) in
acute myeloid leukemia (AML) group (P = .018). The sVEGF levels at diagnosis (range: 2 -640 pg/mL; median 89 pg/mL) was significantly lower compared to remission values (range: 116 -1960 pg/mL; median 136 pg/mL) in patients with
acute lymphoblastic leukemia (ALL) (P = .002). In ML group, including
Burkitt's lymphoma (BL), T-cell
non-Hodgkin's lymphoma (NHL), and
Hodgkin's lymphoma (HL), sVEGF levels at diagnosis were higher than remission levels, but there was no statistically significant difference (P >.05). On the other hand, there were significant difference between levels in active disease and control group, ie, BL versus control, T-cell NHL versus control, and HL versus control (P = .008, P = .043, P = .007, respectively). The authors noticed that sVEGF levels showed distinct behavioral pattern in different childhood
malignancies at diagnosis and in remission. In acute
leukemia and ML patients,
VEGF acts through different pathophysiological mechanisms, in both bone marrow (BM) angiogenesis and lymphoid tissue lymphangiogenesis.